Algorae Pharmaceuticals Company Description

Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand.

The company’s product pipeline includes AI-116, a novel combination drug candidate, which includes cannabidiol and an off-patent pharmaceutical ingredient for the of treatment for dementia, including Alzheimer’s disease; NTCELL, an alginate coated capsule to target the treatment of Parkinson’s disease; and AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient to treat cardiovascular disease, including hypertension.

It is also developing AlgaraeOS in partnership with the University of New South Wales, an artificial intelligence platform for biopharmaceutical prediction of both fixed dose combination drug targets and repurposed drug targets agnostic to medical indication.

The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023.

Algorae Pharmaceuticals Limited was founded in 1987 and is based in Melbourne, Australia.

Algorae Pharmaceuticals Limited

Country	Australia
Founded	1987
Industry	Biotechnology
Sector	Healthcare
Employees	48
CEO	David Hainsworth

Contact Details

Address: Rialto South Tower Melbourne, 3000 Australia
Phone	61 2 9698 5414
Website	algoraepharma.com

Stock Details

Ticker Symbol	1AI
Exchange	Australian Securities Exchange
Fiscal Year	July - June
Reporting Currency	AUD
ISIN Number	AU000000LCT6
SIC Code	2836

Key Executives

Name	Position
David Richard Hainsworth	Chief Executive Officer and Executive Chairman
Dr. Carolyn M. Sue A.M., B.S., Ph.D.	Member of Medical Advisory Board and Chief Medical Officer of NTCELL
Dr. James A. Mckenna	Chief Scientific Officer
Vishal Shah	Chief Commercial Officer
Jennifer Voon	Company Secretary